Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

This Phase 3 clinical study is designed to evaluate the safety, tolerability, and efficacy of two dose levels of Infergen (interferon alfacon-1, CIFN) plus Ribavirin administered daily for 48 weeks and no treatment in patients chronically infected with hepatitis C who are nonresponders to previous pegylated interferon alfa plus ribavirin therapy. Patients are randomized 1:1:1 to receive Interferon Alfacon-1 (9 or 15 µg) + Ribavirin (both administered daily) or no treatment for up to 48 weeks. The protocol and informed consent form that will be used must be approved by the Investigator\'s Institutional Review Board (IRB)/Independent Ethics Committee (IEC) before the study is initiated.